0
Retrophin, Inc. Banner Image

Retrophin, Inc. has reached its limit for free report views

Work for Retrophin, Inc.? Upgrade Your Profile and unlock all your annual reports.

Retrophin, Inc.

  • Ticker RTRX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Retrophin, Inc. Logo Image
  • 201-500 Employees
  • Based in San Diego, California
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressiveMore scarring of the kidney often leading to end-stage kidney disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Retrophin, Inc.

Most Recent Annual Report

Retrophin, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Retrophin, Inc. has reached its limit for free report views.

Older/Archived Annual Reports